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Abstract
Background: Studies indicate that strength training has beneficial effects on clinical health outcomes in prostate
cancer patients during androgen deprivation therapy. However, randomized controlled trials are needed to
scientifically determine the effectiveness of strength training on the muscle cell level. Furthermore, close
examination of the feasibility of a high-load strength training program is warranted. The Physical Exercise and
Prostate Cancer (PEPC) trial is designed to determine the effectiveness of strength training on clinical and muscle
cellular outcomes in non-metastatic prostate cancer patients after high-dose radiotherapy and during ongoing
androgen deprivation therapy.
Methods/design: Patients receiving androgen deprivation therapy for 9-36 months combined with external high-
dose radiotherapy for locally advanced prostate cancer are randomized to an exercise intervention group that
receives a 16 week high-load strength training program or a control group that is encouraged to maintain their
habitual activity level. In both arms, androgen deprivation therapy is continued until the end of the intervention
period.
Clinical outcomes are body composition (lean body mass, bone mineral density and fat mass) measured by Dual-
energy X-ray Absorptiometry, serological outcomes, physical functioning (muscle strength and cardio-respiratory
fitness) assessed with physical tests and psycho-social functioning (mental health, fatigue and health-related quality
of life) assessed by questionnaires. Muscle cellular outcomes are a) muscle fiber size b) regulators of muscle fiber
size (number of myonuclei per muscle fiber, number of satellite cells per muscle fiber, number of satellite cells and
myonuclei positive for androgen receptors and proteins involved in muscle protein degradation and muscle
hypertrophy) and c) regulators of muscle fiber function such as proteins involved in cellular stress and
mitochondrial function. Muscle cellular outcomes are measured on muscle cross sections and muscle homogenate
from muscle biopsies obtained from muscle vastus lateralis.
Discussion: The findings from the PEPC trial will provide new knowledge on the effects of high-load strength
training on clinical and muscle cellular outcomes in prostate cancer patients during androgen deprivation therapy.
Trial registration: ClinicalTrials.gov: NCT00658229
Keywords: Strength training, Prostate cancer, Androgen deprivation therapy, Clinical and muscle cellular outcomes
* Correspondence: lene.thorsen@oslo-universitetssykehus.no
† Contributed equally
1Department of oncology, Oslo university hospital, Oslo, Norway
Full list of author information is available at the end of the article
Thorsen et al. BMC Cancer 2012, 12:123
http://www.biomedcentral.com/1471-2407/12/123
© 2012 Thorsen et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
Background
Prostate Cancer (PC) is the most frequent diagnosed
malignancy in men in Europe and North America. The
risk of PC increases with age, and the median age of
onset is approximately 70 years. Treatment depends on
stage, histology and the serum PSA level, beside the
patients’ general health and age. Radiotherapy combined
with androgen deprivation therapy (ADT) is used in
patients with locally advanced tumors and/or those with
high Gleason scores, characterized as intermediate or
high-risk profiles [1]. ADT has potentially negative
effects on several clinical outcomes, such as muscle
atrophy [2].
Physical exercise during and after cancer treatment
has been shown to be effective to reduce several nega-
tive clinical consequences followed by cancer and cancer
treatment [3,4]. Compared to breast cancer patients
relatively few studies in PC patients have been published
[4,5]. More evidence on the efficacy of strength training
on clinical outcomes in PC patients is therefore desir-
able. At the same time more attention should be paid to
the effect of ADT on the muscle cell level because the
reduced testosterone levels influence the underlying reg-
ulators of muscle mass and muscle function. Further-
more, the effects of strength training on the same
regulators are of particular interest during ADT, and as
far as we know they have not previously been explored
in PC patients.
Ageing is associated with a reduction in muscle mass,
typically by 1-2% per decade from the age of 30 to the
age of 50. Thereafter the rate of muscle loss increases
progressively to 10% per decade [6]. It is well known
that decreased levels of serum testosterone are followed
by reduced muscle mass [7,8]. In PC patients treated
with ADT for 6-12 months, lean body mass (LBM) has
been reported to decrease by 3% [9]. This reduction
may affect muscle strength markedly because muscle
mass is the dominant tissue in LBM.
Loss of bone mineral density (BMD) has been
observed in PC patients on ADT [10,11]. It has also
been shown that ADT increases body weight and fat
mass in these patients [9]. Decreased levels of testoster-
one and body changes during ADT, may also influence
mental health, fatigue and health-related quality of life
(HRQOL) in PC patients [12,13].
Total skeletal muscle mass reflects the size of all indivi-
dual muscle groups in the body. Furthermore, the size of
each muscle group is primarily determined by the size of
the individual muscle fibers1, and to a lesser extent by
the number of fibers. Regulation of muscle fiber size is
first and foremost driven by an increase in the number
and size of myofibrils (contractile proteins) within the
muscle fiber (Figure 1). This process is normally
supported by an increased number of satellite cells and
(often) increased number of myonuclei (Figure 1). Impor-
tantly, satellite cells seem to play a significant role in reg-
ulation of muscle fiber size. Satellite cells are
mononuclear progenitor cells that are found between the
sarcolemma and the basement membrane in the muscle
fibers (Figure 1 and Additional file 1). Satellite cells are
normally in a quiescent state, but are activated by ade-
quate stimuli (e.g. strength training). Upon activation the
satellite cells donate their nuclei to the existing muscle
fibers and thus facilitate skeletal muscle hypertrophy by
increasing the protein synthesis [14]. During regeneration
after muscle injury, satellite cells may also fuse and
thereby form new mature muscle fibers [14]. In addition,
satellite cells seem to support muscle hypertrophy by
production of local growth factors (e.g. IGF-1) [15].
In the muscle tissue, testosterone stimulates both the
muscle protein synthesis in muscle fibers and activation
of satellite cells through the interaction with the andro-
gen receptor [16]. Consequently, graded dosage of tes-
tosterone has been shown to both increase the muscle
fiber size, reflected by increased muscle fiber cross sec-
tional area, and number of satellite cells in a dose
dependent pattern [17,18]. Suppression of testosterone
reduces the positive stimuli on muscle protein synthesis,
and patients treated with ADT experience reduced LBM
[19,20]. Low levels of testosterone might also influence
the regulation of muscle mass through its inhibition of
the ubiquitin-proteasome system [21]. Consequently,
ADT might facilitate muscle atrophy both by inhibiting
important pathways involved in muscle hypertrophy, as
well as stimulating pathways involved in protein
degradation.
Muscle strength is mainly determined by the size of
muscles, but other qualities of muscles, such as endur-
ance and stress tolerance, are more related to the con-
tent and function of stress proteins and proteins
involved in the mitochondrial function [22,23]. Interest-
ingly, castration has been shown not only to reduce
muscle fiber size, but also to affect the mitochondrial
structure negatively in rat muscles [24]. Furthermore,
castration seems to reduce the stress induced up-regula-
tion of stress proteins in heart muscle [25]. Whether
castration also affects the stress protein response and
mitochondrial function in human skeletal muscles is
currently not known.
Effects of strength training
Strength training has the potential to increase muscle
mass and BMD in both young and elderly males and
females [26-29]. Although the response to strength
training differs among individuals, most studies report
an increase in muscle fibre cross sectional area by 10-
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60% over 9-30 weeks of training [30]. Furthermore, an
increase in BMD from 1 to 4% has been observed over
16-52 weeks of strength training [27,31-33].
Effectiveness of exercise on clinical outcomes has been
reported in numerous studies in cancer patients.
Research has so far shown promising effects on among
others muscle strength, aerobic fitness, fatigue, anxiety
and quality of life [3,4]. However, the effect of exercise
during ADT in PC patients has been less studied [4,5].
These studies have shown positive results in muscular
and aerobic endurance, fatigue and QoL [5,34,35]. Less
promising is the effect of physical exercise on body-
composition endpoints. It could therefore be hypothe-
sized that ADT compromises some important cellular
signals regulating the exercise induced increase in lean
body mass with strength training.
The increase in muscle fiber size in response to
strength training seems to be dependent, at least to some
extent, on satellite cell activation in order to incorporate
new myonuclei in the growing muscle fiber [14]. In
healthy subjects, strength training increases the number
of myonuclei and the number of satellite cells in both
young and elderly individuals [36,37] (Figure 2). The
mechanisms behind the activation of satellite cells during
strength training in humans are not fully understood, but
changes in local growth factors and testosterone interac-
tions seem to be important [38]. Whereas reduced levels
of testosterone during ADT negatively affect the regula-
tion of muscle mass, strength training might counteract
these detrimental effects on muscle fibres (Figure 2). On
the other hand, it might be that the very low testosterone
levels, comparable with castration, blunt the effects of
strength training in these patients. Interestingly, healthy
young men treated with a GnRH analog over 12 weeks
showed the same increase in mRNA of important local
growth factors in response to strength training as placebo
treated controls [39]. Nevertheless, the accumulation of
muscle mass during the strength training intervention
was reduced in the testosterone-suppressed group com-
pared to the placebo treated controls [40].
The effects of strength training on mitochondrial
function and protection against cellular stress in muscle
fibers are less studied than the effect on muscle size.
Nevertheless, in previously untrained healthy men
strength training has been observed to positively affect
both mitochondrial proteins and stress proteins [41,42].
Consequently, strength training has the potential to
counteract several negative effects of ADT on muscle
size and function.
To our knowledge no previous studies have investi-
gated the effect of strength training on the regulation of
muscle size and of muscular function on a cellular level
in PC patients during ADT. Furthermore, previous clini-
cal data need to be confirmed. Here, we present the
design and methods of an ongoing trial called the Physi-
cal Exercise and Prostate Cancer (PEPC) trial, which
aims to explore the effects of strength training on clini-
cal outcomes as well as explore mechanisms of the
effect on muscle cellular outcomes in patients with PC
during ongoing (neo)-adjuvant ADT.
Aims
The overall aims of the PEPC trial are to evaluate the
effectiveness of a high-load 16 week strength training
Figure 1 A schematic drawing of a muscle fiber (muscle cell) in longitudinal- and cross sectional plane. The muscle fiber is surrounded
by two membranes, the plasma membrane (inner) and the basal lamina (outer). The satellite cells are located between these two
membranes, and just beneath the plasma membrane lays the myonuclei. The contractile proteins in the muscle cell are arranged in myofibrils.
In the longitudinal plane you see that the myofibrils are organized into sarcomeres separated by the z-disc and the mitochondria are seen as
circular spots between the myofibrils.
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program on a) clinical outcomes including serological
parameters such as lipid profile (low and high density
lipoprotein cholesterol) and low grade inflammation (C-
reactive protein (CRP)) b) muscle cellular outcomes as
muscle fiber size, regulators of muscle fiber size and
regulators of muscle fiber function and c) feasibility of a
high-load strength training program in PC patients who
at intervention start have discontinued their high-dose
radiotherapy and are on ongoing (neo)-adjuvant ADT
throughout the intervention period.
Methods/design
This study is a randomized clinical trial with two arms
comparing an exercise intervention group (EG) that
receives a 16 week high-load strength training program
with a control group (CG) that is encouraged to main-
tain their habitual activity level and not start strength
training. The study has been approved by the Regional
Committee for Medical and Health Research Ethics,
South-East Region (protocol nr. 08/212b.2008/4062).
Participants
Patients are included from two oncological units at Oslo
University hospital, the Norwegian Radium Hospital
(NRH) and Ullevaal University Hospital (UUH). All
patients must fulfill the following eligibility criteria 1)
PC cancer of intermediate or high-risk profiles, 2) high-
dose radiotherapy with or without two high-dose-rate
brachytherapy fractions [43], 3) (neo)-adjuvant ADT by
commercially available LHRH analogue for 9-36 months.
The most important inclusion and exclusion criteria are
1) less than one hour car drive between the patient’s
residence and the place of training or 2) current regular
strength training. All inclusion and exclusion criteria are
listed in Additional file 2.
In addition to written information, eligible patients are
verbally informed about the study by their responsible
radiotherapist and the study coordinator usually during
or immediately after radiotherapy. After giving their
written consent agreeing patients are scheduled for pre-
intervention assessments usually 1-2 months after radio-
therapy, which are repeated one week after the interven-
tion period (Figure 3).
Randomization
At completion of the pre-intervention assessments
patients are randomized in a 1:1 ratio to the EG or CG,
stratified for hospital. Randomization is computerized
and performed by the staff at the clinical research office
at NRH.
Figure 2 Schematic muscular adaptations to strength training in healthy men and PC patients on ADT. Schematic muscular adaptations
to strength training in healthy men (A), possible consequences of ADT on muscle fibers in PC patients (B), and possible muscular adaptations to
strength training in PC patients on ADT (C). In A), the muscle fiber cross sectional area is increased as a result of an increase in the number and
size of myofibrils within the muscle fiber, and this increase in size is supported by an increased number of satellite cells and (often) increased
number of myonuclei. In B), ADT results in decreased muscle fiber cross sectional area and reduced muscle function. In C), muscle fiber cross
sectional area and muscle function is normalized in ADT treated PC patients on strength training.
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Intervention
The exercise intervention starts 5-10 months on ADT,
one week after the pre-intervention assessment (Figure
3). The intervention is performed at the Norwegian
School of Sport Sciences (NSSS) in Oslo.
The EG follows a modified resistance exercise pro-
gram originally tested by Segal et al. [44]. Compared to
the original program the intensity (training load) and
duration are increased in order to potentially increase
the effect of the strength training on LBM/body compo-
sition (Table 1). The patients perform three strength
training sessions per week. Two of these sessions are
performed under supervision by qualified instructors, to
ensure safety, technique and progression in training
load, with a maximum of three patients per instructor.
The mid-week session, without the instructor, is per-
formed at moderate intensity alone or together with
other trial participants at NSSS. In each training set, the
patient documents the training load and rate of exhaus-
tion in an exercise log.
Each session consists of one to three sets of nine
strength training exercises, performed at an intensity of
6 or 10 repetitions maximum (6-10 RM: the load that
induces technique failure in 6 or 10 repetitions). The
two first weeks of the program are considered to repre-
sent familiarization to the exercise protocol for the
patients, and are performed at a light load (40-50% of
one repetition maximum (1 RM)) in sets of 10 repeti-
tions. The exercises performed are: smith machine
squat, leg press, standing calf raises, knee flexion, knee
extension, chest press, seated rows, shoulder press and
preacher biceps curl (training equipment provided by
Technogym, Italia).
Prior to the strength training session the patients per-
form 10 minutes of warm up on an exercise ergometer.
In addition, the patients complete a sub maximal set of
10 repetitions as a specific warm-up in the squat exer-
cise prior to every training session. After the two first
weeks the patients are instructed to gradually increase
the training load, in order to perform the exercise with
DXA DXA
Bloodtests Bloodtests
Physical tests Physical tests
Questionnaire Questionnaire
Muscle biopsy Muscle biopsy
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T
Figure 3 Timeline in the PEPC trial. Different duration of ADT related to different risk groups and somehow different treatment strategies in
the two hospitals. Importantly all patients are on ADT at pre- and post-intervention assessments.
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the highest load possible during the prescribed number
of repetitions per set on the two sessions with heavy
intensity. From experience, this means that they increase
the resistance by 2-5% per week through the 16 weeks
period.
Patients in the CG are encouraged to maintain their
habitual activity level and not start strength training. In
order to increase the participation rate and reduce the
dropout rate, the patients in the CG are offered the
exercise intervention after the post-intervention
assessment.
Outcomes and assessments
Both clinical and muscle cellular outcomes are collected
before the intervention (pre-intervention assessments)
and after the intervention (post-intervention assess-
ments) (Figure 3). All outcomes, specific variables and
assessments in the PEPC trial are listed in Additional
file 3.
Clinical outcomes
Body composition LBM, BMD and fat mass are mea-
sured by dual-energy X-ray absorptiometry (DXA) using
a Hologic multiple detector, fan-beam bone densit-
ometer (Discovery QDR series). LBM is measured in
arms, legs, trunk and total body. Changes in upper and
lower body LBM are investigated separately because of
differences in androgen sensitivity in leg muscles com-
pared to neck, chest and shoulder muscles [45]. Body
weight is measured by a digital platform scale and
height by a stadiometer and body mass index (weight/
(height)2) is calculated.
Serological outcomes Fasting blood tests are taken
between 8:00 am and 9:00 am. The tests analyzed are
listed in Additional file 3. A biobank for frozen serum
and full blood (EDTA) is established.
Physical functioning Muscle strength is measured by 1
RM test, sit-to-stand test and stair-climbing test [46]
and cardio-respiratory fitness is measured by Shuttle
Walk test.
To secure validity of the physical tests, all patients
undergo a session of familiarization to the actual tests
3-4 days prior to the pre- and post intervention assess-
ments. Both sessions are performed based on the same
guidelines, but after the familiarization session the load
of each exercise is adjusted to match the expected 1
RM. Additional description of the physical functioning
assessments is provided in Additional file 4.
Psycho-social functioning Mental health are self-rated
by the Hospital Anxiety and Depression scale (HADS)
[47], fatigue is assessed by the Norwegian version of
Fatigue Questionnaire (FQ) [48] and HRQOL by The
European Organization and Treatment of Cancer Qual-
ity of Life Questionnaire (EORTC QLQ C-30) [49].
Additional description of the psycho-social functioning
assessments is provided in Additional file 4.
Muscle cellular outcomes
Muscle biopsies are obtained from approximately half of
the patients included in the study. Patients not willing
to undergo biopsy are still eligible for trial participation.
With the patients in a supine position, a 6 mm
Pelomi-needle (Albertslund, Denmark) with manual suc-
tion is used to obtain muscle samples (≈ 200 mg), under
local anaesthesia (Xylocain® adrenaline, 10 mg·ml-1 + 5
μg·ml-1, AstraZeneca, Södertälje, Sweden). Before the
intervention the biopsy is obtained from the mid-section
of the right vastus lateralis, and after the intervention
the biopsy is obtained 3 cm proximal to the pre-inter-
vention biopsy.
Muscle fibre size and regulators of muscle fibre size
Muscle fiber size, measured as muscle fiber cross sec-
tional area, represents the primary muscle cellular out-
come. Secondary muscle cellular outcomes reflecting
regulators of muscle fibre size are a) number of myonu-
clei per muscle fiber b) number of satellite cells per
Table 1 The strength training program
Week 1. Session: heavy intensity 2. Session: moderate intensity 3. Session: heavy intensity
Monday Wednesday Friday
1 and 2 2 × 10 sub maximal resistance 2 × 10 sub maximal resistance 2 × 10 sub maximal resistance
Focus on correct technique Focus on correct technique Focus on correct technique
3 to 6 2 × 10 RM leg exercises 2 × 10 reps. leg exercises 3 × 6 RM leg exercises
1 × 10 RM upper body 2 × 10 reps. upper body 2 × 6 RM upper body
(resistance: 90% of 10 RM)
7 to 12 3 × 10 RM leg exercises 2 × 10 reps. leg exercises 3 × 6 RM leg exercises
2 × 10 RM upper body 2 × 10 reps. upper body 2 × 6 RM upper body
(resistance: 90% of 10 RM)
13 to 16 3 × 10 RM leg exercises 3 × 10 reps. leg exercises 3 × 6 RM leg exercises
3 × 10 RM upper body 3 × 10 reps. upper body 3 × 6 RM upper body
(resistance: 90% of 10 RM)
RM - repetitions maximum, reps - repetitions
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muscle fiber, c) number of satellite cells and myonuclei
positive for androgen receptors and d) proteins involved
in muscle protein degradation (muscle breakdown);
Forkhead Box Protein O (FOXO), Ubiquitin ligase E2
and Myostatin and muscle hypertrophy; androgen recep-
tors and growth factors such as Insulin like growth fac-
tor 1 (IGF1) and Mechano growth factor (MGF).
Muscle fibre cross sectional area and regulators of
muscle fibre size are analysed by immunohistochemistry
on cross sections of muscle biopsies and by western
blots and enzyme-linked immunosorbent assay (ELISA)
in muscle homogenate.
Muscle fibre cross sectional area will be measured by
cutting transverse serial sections of the muscle biopsy (8
μm thick) with a cryostat microtome (Microm, Ger-
many) at -22°C and mounted on glass slides. Serial sec-
tions are immunohistochemically stained for fibre types
(type I and type II) (used to measure muscle fibre cross
sectional area), number of satellite cells, number of
myonuclei and number of satellite cells and myonuclei
positive for androgen receptors. Muscle fibre cross sec-
tional area is measured for the different fibre types sepa-
rately. An image of a satellite cell and basal lamina
staining on a cross section from a muscle biopsy is
shown in Additional file 1.
Regulators of muscle fibre function Regulators of mus-
cle fibre function studied in this project are proteins
involved in the protection against cellular stress; heat
shock proteins (HSP) 27 and HSP 70), as well as
enzymes involved in mitochondrial function; Cyto-
chrome C Oxidase 4 (Cox 4), Hsp 60 and Citrate
synthase. These regulators are measured by western
blots and ELISA.
Feasibility
The feasibility of the PEPC trial is investigated by exam-
ining the eligibility, compliance, attrition and safety
among those considered for inclusion and those partici-
pating. This involves registration of a) the number of
eligible patients among all PC patients receiving radio-
therapy combined with ADT, b) the number of patients
willing to participate among the eligible patients and c)
compliance and adherence to the intervention programs
and reasons for missing exercise sessions and
discontinuation
Background variables
The patients provide information about partnership,
number and age of children living at home, education,
work and sick leave by filling out a questionnaire. Infor-
mation about medical situation as time points for treat-
ment, stage of disease and comorbidity are collected
from the medical record. Past illnesses and other medi-
cal problems are also reported in the questionnaire.
Lifestyle outcomes The level of physical exercise is
assessed by a modified Norwegian version of the Leisure
Score Index (LSI) from the Godin Leisure-Time Exercise
Questionnaire (GLTEQ) [50]. Dietary habits are assessed
by a modified version of the SmartDiet - a short food
questionnaire [51]. Smoke- and snuff habits are mea-
sured by two single questions; Do you smoke? “Yes
daily”, “Yes, now and then”, “I smoked earlier but I have
stopped” and “No, I have never smoked” and Do you
take snuff? “Yes, daily”, “Yes, now and then”, “I snuffed
earlier but I have stopped” and “No, I have never
snuffed”.
Sample size and statistical considerations
LBM is the primary endpoint of the study. Sample size
calculation is based on comparing the clinically relevant
difference in change before and after the 16 weeks per-
iod in LBM between the EG and CG. To detect a 3 kilo-
grams difference in change between the groups, and
assuming a standard deviation (SD) of 3 kilograms, 22
patients are needed in each group with a significance
level (two sided) of 5% and a power of 90%. Due to
dropouts we plan to include 30 patients in each group.
According to previous studies, this number should also
be sufficient to detect differences in the cellular muscle
outcomes (Sinha-Hikim et al., 2006).
Changes in outcome variables from start of interven-
tion will be compared between the EG and CG groups
by analysis of covariance using the baseline measure-
ment as a covariate. P-values below 5% will be regarded
as statistically significant. If obvious deviations from
normal distributions are detected, changes in outcome
will be compared between groups by Wilcoxon-Mann-
Whitney test. The primary analysis population will be
the intention to treat population using last observation
carried forward to impute any missing values. In addi-
tion a per-protocol analysis including only patients with
no missing observations of the variable of interest will
be performed. Should imbalances in important variables
be detected sensitivity analyses will also be added
including these as covariates in the model.
Discussion
Previous research has examined the effect of physical
exercise on clinical outcomes such as body composition,
physical function, mental health, fatigue and quality of
life in PC patients [3-5]. Still research on the effect of
physical exercise in this patients group is less extensive
than in other cancer groups, such as for example
patients with breast cancer. Two of the most pro-
nounced clinical side effects of ADT are the negative
effect on muscle mass and muscle strength. However,
studies investigating the effects of ADT and exercise at
the muscle cell level are still lacking. Expanded knowl-
edge in this field among PC patients is therefore
required.
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The clinically indicated ADT in PC patients enables
the study of testosterone’s role in regulation of muscle
mass during strength training. The main question is
whether normal adaptations to strength training are dis-
turbed when the level of testosterone is below 1 nmol/L
(castration level); e.g. is the activation of satellite cells
and hypertrophic effect of strength training blunted in
these patients? Furthermore, by investigating important
factors for the regulation of muscle mass and muscle
function, the cellular effects of ADT on muscle tissue
will be elucidated. Currently, three other ongoing trials
are investigating the effect of exercise on muscular out-
comes assessed by muscle biopsies in patients with
breast, lung and testicular cancer receiving chemother-
apy [52-54]. However, the effects of high-load strength
training on muscular adaptations in PC patients during
ADT have not previously been investigated.
Compared to previous studies in PC patients the
intensity and/or duration in our strength training proto-
col is somewhat increased [44,55,56]. The rationale for
choosing a strenuous strength training protocol is the
fact that the effect on total muscle mass has been mod-
erate or absent in previous studies on PC patients. One
possible explanation for negligible effects on muscle
mass in previous studies may be that the stimuli for
muscle hypertrophy have been too low. In healthy men,
it is suggested that a training intensity of 75-80% of 1
RM (6-12 RM sets) combined with multiple sets in each
exercise (starting from 1-2 and progressing to 3-6 sets
per exercise), give optimal stimuli for muscle hypertro-
phy when performed 2-3 times per week [57]. Conse-
quently, in order to maximize the stimuli for muscle
hypertrophy we chose to implement this strength train-
ing protocol in our patients. Importantly the training
protocol should still be tolerable and safe.
Positive findings from the PEPC trial will help in the
construction of more effective training protocols to
counteract the negative effects of ADT on muscle tissue,
BMD and physical function. More importantly, the
results on the cellular effects of ADT in muscle tissue
will provide novel understandings of muscle mass regu-
lation by testosterone. Such knowledge will improve our
understanding on how aging in general and reduced tes-
tosterone production during ADT specifically, induces
loss of muscle mass (sarcopenia). In turn this knowledge
can be used to establish more effective strategies against
sarcopenia in both healthy elderly and in patient popula-
tions at risk. New strategies could include both new
medical treatments and training strategies focused to
overcome the cellular changes inducing sarcopenia.
Summary
Knowledge of the effect of exercise on clinical outcomes
such as physical functioning and quality of life outcomes
has increased over the last decades. Studies testing aero-
bic exercise in breast cancer patients are most frequent.
Studies in other cancer groups testing the effects of
strength training program are still lacking. The PEPC
trial focuses on the effect on a high-load strength train-
ing program on both clinical and muscle cellular out-
comes in PC patients during ADT. As far as we know
this is the first study having a muscular cellular outcome
in these patients. By testing a high-load strength training
program the study will provide new knowledge on opti-
mal training programs in PC patients.
Endnote
1The term muscle fiber (muscle cell) originates from the
embryonic formation of mature muscle cells where
mononuclear myoblasts fuse to the giant multinuclear
muscle cells.
Additional material
Additional file 1: An image of a satellite cell and basal lamina
staining on a cross section from a muscle biopsy.
Additional file 2: Inclusion and exclusion criteria.
Additional file 3: Outcomes, specific variables and assessments.
Additional file 4: Descriptions of assessments.
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